Publications by authors named "Zhouming Wang"
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a serious condition associated with systemic lupus erythematosus (SLE), and the study explores how extracellular vesicles (EVs) might play a role in its pathogenesis.
- The research involved 18 SLE-PAH patients, 36 SLE patients without PAH, and 36 healthy controls, using flow cytometry to analyze different types of circulating EVs.
- Key findings indicate that various subgroups of EVs (like LEVs and PEVs) were significantly elevated in SLE-PAH patients, suggesting they could serve as potential biomarkers for predicting PAH severity in SLE patients.
Background: Long-term clinical outcomes after pulmonary artery denervation (PADN) in patients with Group 1 pulmonary arterial hypertension (PAH) have not been reported.
Aims: We aimed to investigate the effect of PADN on 1-year outcomes in patients with PAH.
Methods: In the multicentre PADN-CFDA trial, 128 patients with Group 1 PAH were randomly assigned to PADN plus a phosphodiesterase-5 inhibitor (PDE-5i) versus a sham PADN procedure plus a PDE-5i.
Background: The differential treatment effect of pulmonary artery denervation (PADN) in pulmonary arterial hypertension (PAH) patients with different risk burdens remains unclear. This study aimed to determine the effectiveness of PADN in low vs intermediate-high-risk PAH patients.
Methods: In total, 128 patients with treatment naive PAH included in the PADN-CFDA trial were categorized into low-risk and intermediate-high-risk patients.
Background: World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) is a progressive, debilitating disease. Previous observational studies have demonstrated that pulmonary artery denervation (PADN) reduces pulmonary artery pressures in PAH. However, the safety and effectiveness of PADN have not been established in a randomized trial.
View Article and Find Full Text PDF